Osimertinib in pre-treated poor PS patients with T790M-positive advanced NSCLC

Phase 2

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000023823
• Lead Sponsor: orth East Japan Study Group (NEJSG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-01
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with active double cancer for 5years 2) Interstitial pneumonia 3) Poor oral intake 4) History of using immunocheckpoint therapy 5) History of taking osimertinib medication 6) The infection requiring systemic treatment 7) Patients with psychosis or psychotic symptoms is determined to be difficult to participants in a clinical trial 8) Patients with symptomatic brain metastases 9) Uncontrolled diabetes 10) Serious complications 11) Patients during systemic administration steroids therapy over 4weeks 12) Poor PS due to complication 13) A pregnant woman, a woman in breast-feeding 14-15) Patients with severe heart disease 16) Prior radiotherapy for primary or metastasis evaluable lesion 17) Patients with severe hypersensitivity 18) Patients with corneal ulcer 19) An inappropriate case judged by doctor in charge

Study & Design

• Study Type: Interventional
• Study Design: Not specified